KBC Group NV Has $3.85 Million Stock Holdings in Natera, Inc. $NTRA

KBC Group NV trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 41.9% during the 1st quarter, HoldingsChannel reports. The fund owned 19,252 shares of the medical research company’s stock after selling 13,866 shares during the quarter. KBC Group NV’s holdings in Natera were worth $3,850,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Robinhood Asset Management LLC bought a new stake in shares of Natera during the 4th quarter valued at $12,981,000. J. Safra Sarasin Holding AG bought a new position in Natera in the 4th quarter worth $2,825,000. UBS Group AG increased its stake in Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Natera by 25.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company’s stock worth $11,476,000 after buying an additional 9,424 shares in the last quarter. Finally, Dakota Wealth Management bought a new stake in Natera during the fourth quarter valued at about $1,356,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NTRA shares. Robert W. Baird set a $265.00 price objective on Natera in a research report on Friday, May 8th. Canaccord Genuity Group increased their target price on Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. UBS Group set a $260.00 target price on Natera in a research note on Wednesday, June 24th. Piper Sandler reissued an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Finally, Guggenheim upped their price target on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $267.83.

Natera Stock Up 0.2%

Shares of NTRA stock opened at $264.69 on Friday. The company’s fifty day simple moving average is $239.24 and its two-hundred day simple moving average is $221.33. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The stock has a market cap of $37.91 billion, a P/E ratio of -162.39 and a beta of 1.51.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the sale, the insider directly owned 134,643 shares in the company, valued at approximately $36,744,074.70. The trade was a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 178,872 shares of company stock valued at $39,627,696. 5.05% of the stock is owned by insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.